These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33051133)

  • 1. Effects of hydroxyurea on cytotoxicity, inflammation and oxidative stress markers in neutrophils of patients with sickle cell anemia: dose-effect relationship.
    Pedrosa AM; Leal LKAM; Lemes RPG
    Hematol Transfus Cell Ther; 2021; 43(4):468-475. PubMed ID: 33051133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of a Selective Inhibitor of Phosphodiesterase-9 on Oxidative Stress, Inflammation and Cytotoxicity in Neutrophils from Patients with Sickle Cell Anaemia.
    Barbosa MC; de Jesus dos Santos TE; dos Santos TN; Pedrosa AM; Elias DB; Leal LK; de Araújo Lopes A; Sasahara GL; Gonçalves Lemes RP
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):271-8. PubMed ID: 26346295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
    Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
    J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
    Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
    Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.
    Renó CO; Barbosa AR; de Carvalho SS; Pinheiro MB; Rios DR; Cortes VF; Barbosa LA; Santos HL
    Ann Hematol; 2020 May; 99(5):937-945. PubMed ID: 32166377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome.
    Connes P; Möckesch B; Tudor Ngo Sock E; Hardy-Dessources MD; Reminy K; Skinner S; Billaud M; Nader E; Tressieres B; Etienne-Julan M; Guillot N; Lemonne N; Hue O; Romana M; Antoine-Jonville S
    Eur J Haematol; 2021 Jun; 106(6):800-807. PubMed ID: 33629431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
    Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
    Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte chemoatractant protein-1: a potential biomarker of renal lesion and its relation with oxidative status in sickle cell disease.
    dos Santos TE; Gonçalves RP; Barbosa MC; da Silva GB; Daher Ede F
    Blood Cells Mol Dis; 2015 Mar; 54(3):297-301. PubMed ID: 25500149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway.
    Nader E; Grau M; Fort R; Collins B; Cannas G; Gauthier A; Walpurgis K; Martin C; Bloch W; Poutrel S; Hot A; Renoux C; Thevis M; Joly P; Romana M; Guillot N; Connes P
    Nitric Oxide; 2018 Dec; 81():28-35. PubMed ID: 30342855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management.
    Gour A; Kour D; Dogra A; Manhas D; Wazir P; Digra SK; Kumar A; Nandi U
    Toxicol Appl Pharmacol; 2022 Aug; 449():116113. PubMed ID: 35691369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters.
    Yahouédéhou SCMA; Carvalho MOS; Oliveira RM; Santiago RP; da Guarda CC; Carvalho SP; Ferreira JRD; Aleluia MM; Adorno EV; Gonçalves MS
    Dis Markers; 2018; 2018():6105691. PubMed ID: 29619129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.
    Silva DG; Belini Junior E; Carrocini GC; Torres Lde S; Ricci Júnior O; Lobo CL; Bonini-Domingos CR; de Almeida EA
    BMC Med Genet; 2013 Oct; 14():108. PubMed ID: 24106994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-27 and interleukin-37 are elevated in sickle cell anemia patients and inhibit in vitro secretion of interleukin-8 in neutrophils and monocytes.
    Alagbe AE; Justo Junior AS; Ruas LP; Tonassé WV; Santana RM; Batista THC; Domingos IF; Araujo AS; Bezerra MAC; Santos MNN; Blotta MHSL
    Cytokine; 2018 Jul; 107():85-92. PubMed ID: 29221667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with sickle cell anemia.
    Itokua KE; Makulo JR; Lepira FB; Aloni MN; Ekulu PM; Sumaili EK; Bukabau JB; Mokoli VM; Longo AL; Kajingulu FM; Zinga CV; Nlandu YM; Engole YM; Akilimali PZ; Ngiyulu RM; Gini JL; Nseka NM
    BMC Nephrol; 2016 Nov; 17(1):178. PubMed ID: 27855647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with
    Ndidi US; Adanho CSA; Santiago RP; Yahouédéhou SCMA; Santana SS; Mafili VV; Pitanga TN; Fonseca CA; Ferreira JRD; Adorno EV; Lyra IM; Adekile AD; Barbosa CG; Goncalves MS
    Dis Markers; 2019; 2019():1580485. PubMed ID: 31636731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.